Advanced search    

Search: authors:"Davorka Tomic"

5 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis

employee of Novartis Pharma AG during the time of manuscript preparation. Shannon Ritter and Davorka Tomic are employees of Novartis Pharma AG. Open Access This article is distributed under the terms of the

Optimizing treatment success in multiple sclerosis

. Filipe Palavra received speaking honoraria and travel expenses for scientific meetings from Bayer Healthcare, Biogen, Merck Serono, Novartis Pharma, Sanofi and Teva Pharmaceuticals. Davorka Tomic is an

No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis

analysis. Richard Nixon and Niklas Bergvall conceived and designed the study, analyzed the data, interpreted the results, and critically reviewed and approved the manuscript. Davorka Tomic, Nikolaos Sfikas ... this assistance was funded by Novartis Pharma AG. Conflict of interest. Richard Nixon is a paid employee of Novartis Pharma AG. Niklas Bergvall is a paid employee of Novartis Pharma AG. Davorka Tomic is

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

The aim of this study was to evaluate short-term safety and tolerability of fingolimod in a real-world population with relapsing multiple sclerosis, focusing on cardiac safety during treatment initiation. Patients received fingolimod 0.5 mg once daily for four months. Patients excluded from the pivotal studies with certain pre-existing cardiac conditions or baseline cardiac...